公开(公告)号：US20120309842A1

公开(公告)日：2012-12-06

申请号：US13496834

申请日：2010-09-16

Applicant: Sayeed Mukhtar ,  Dinesh Shashidharan Nair ,  Roshan Ramesh Medhane ,  Nitin Maheshwari ,  Hashim Nizar Poovanathil Nagoor Meeran ,  Neera Tewari ,  Mohan Prasad

Inventor： Sayeed Mukhtar ,  Dinesh Shashidharan Nair ,  Roshan Ramesh Medhane ,  Nitin Maheshwari ,  Hashim Nizar Poovanathil Nagoor Meeran ,  Neera Tewari ,  Mohan Prasad

IPC: C07C209/70 ,  A61K31/137 ,  A61P19/08 ,  A61P3/14 ,  A61P19/10 ,  C07C211/30 ,  A61P3/12

CPC classification number: C07C209/68 ,  C07C17/16 ,  C07C29/58 ,  C07C209/08 ,  C07C209/70 ,  C07C211/30 ,  C07C33/483

Abstract: The present invention provides processes and intermediates for preparing cinacalcet base and pharmaceutically acceptable salts thereof.

Abstract translation: 本发明提供了制备西那卡塞碱及其药学上可接受的盐的方法和中间体。

公开(公告)号：US20120220777A1

公开(公告)日：2012-08-30

申请号：US13395922

申请日：2010-09-16

Applicant: Saridi Madhava Dileep Kumar ,  Munish Kapoor ,  Swargam Sathyanarayana ,  Rajesh Kumar Thaper ,  Mohan Prasad

Inventor： Saridi Madhava Dileep Kumar ,  Munish Kapoor ,  Swargam Sathyanarayana ,  Rajesh Kumar Thaper ,  Mohan Prasad

IPC: C07D401/04

CPC classification number: C07D401/04

Abstract: The present invention relates to an in-situ process for the preparation of polymorphic Form A of lenalidomide.

Abstract translation: 本发明涉及用于制备来那度托多晶型A的原位方法。

公开(公告)号：US20120178821A1

公开(公告)日：2012-07-12

申请号：US13388134

申请日：2010-07-30

Applicant: Pranab Chatterjee ,  Asok Nath ,  Mohan Prasad

Inventor： Pranab Chatterjee ,  Asok Nath ,  Mohan Prasad

IPC: A61K31/138 ,  C07C59/265

CPC classification number: C07C217/18 ,  C07C59/265 ,  C07C213/08 ,  C07C213/10

Abstract: The present invention provides a polymorphic form of toremifene citrate and processes for its preparation. It also relates to an improved process for the preparation of the Z isomer of the toremifene base, free of E isomer, and its pharmaceutically acceptable salts.

Abstract translation: 本发明提供了一种多晶型托伐米芬柠檬酸盐及其制备方法。 本发明还涉及制备不含E异构体的托瑞米芬碱的Z异构体及其药学上可接受的盐的改进方法。

公开(公告)号：US08178674B2

公开(公告)日：2012-05-15

申请号：US13100833

申请日：2011-05-04

Applicant: Yatendra Kumar ,  Mohan Prasad ,  Mahivir Singh Khanna ,  Seema Ahuja

Inventor： Yatendra Kumar ,  Mohan Prasad ,  Mahivir Singh Khanna ,  Seema Ahuja

IPC: C07D417/12 ,  A61K31/496 ,  A61P25/18

CPC classification number: C07D417/12

Abstract: The invention relates to processes for the preparation of substantially pure ziprasidone. The invention also relates to the preparation of acid addition salts of ziprasidone. More particularly, it relates to the preparation of substantially pure hydrochloride salt of ziprasidone. The invention also relates to pharmaceutical compositions that include the substantially pure ziprasidone or ziprasidone hydrochloride and use of said compositions for treating schizophrenia.

Abstract translation: 本发明涉及制备基本上纯的齐拉西酮的方法。 本发明还涉及齐拉西酮的酸加成盐的制备。 更具体地说，本发明涉及齐拉西酮基本上纯的盐酸盐的制备。 本发明还涉及药物组合物，其包括基本上纯的齐拉西酮或齐拉昔酮盐酸盐以及所述组合物用于治疗精神分裂症的用途。

公开(公告)号：US20120101272A1

公开(公告)日：2012-04-26

申请号：US13258961

申请日：2010-03-26

Applicant: Balaguru Murugesan ,  Anandam Vempali ,  Swargam Sathyanarayana ,  Rajesh Kumar Thaper ,  Mohan Prasad

Inventor： Balaguru Murugesan ,  Anandam Vempali ,  Swargam Sathyanarayana ,  Rajesh Kumar Thaper ,  Mohan Prasad

IPC: C07D237/34

CPC classification number: C07D239/94

Abstract: The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof. The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a nove-ICrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate.

Abstract translation: 本发明涉及制备式I的厄洛替尼或其药学上可接受的盐的方法。 本发明还涉及制备三氟醋酸埃洛替尼的方法。 本发明还涉及一种名为E型的埃洛替尼三氟乙酸盐的结晶形式及其制备方法。 本发明还涉及从埃罗替尼三氟醋酸盐制备盐酸埃罗替尼的方法。

公开(公告)号：US08080656B2

公开(公告)日：2011-12-20

申请号：US12089297

申请日：2006-10-05

Applicant: Asok Nath ,  Hiten Sharadchandra Mehta ,  Mohan Prasad

Inventor： Asok Nath ,  Hiten Sharadchandra Mehta ,  Mohan Prasad

IPC: C07D413/02 ,  C07D295/00

CPC classification number: C07D265/32 ,  C07D413/06

Abstract: The present invention relates to a highly pure (2R,3S)-4-benzyl-3-(4-fluorophenyl)morpholin-2-yl 3,5-bis(trifluoromethyl)benzoate of Formula II, and a process for its preparation. The present invention further provides a process for preparation of Aprepitant of Formula I or pharmaceutically acceptable salt thereof, using the highly pure compound of Formula II. The present invention also provides a process for preparation of Aprepitant of Formula I or pharmaceutically acceptable salt thereof which comprises of cyclising the compound of Formula VII at elevated temperature, in the absence of solvent.

Abstract translation: 本发明涉及式II的高纯度（2R，3S）-4-苄基-3-（4-氟苯基）吗啉-2-基3,5-双（三氟甲基）苯甲酸酯及其制备方法。 本发明还提供使用高度纯的式II化合物制备式I的阿维地丁或其药学上可接受的盐的方法。 本发明还提供了制备式I的阿维地敏剂或其药学上可接受的盐的方法，其包括在不存在溶剂的情况下在高温下使式VII的化合物环化。

公开(公告)号：US07915422B2

公开(公告)日：2011-03-29

申请号：US11576867

申请日：2005-10-04

Applicant: Neela Praveen Kumar ,  Mahavir Singh Khanna ,  Mohan Prasad ,  Yatendra Kumar

Inventor： Neela Praveen Kumar ,  Mahavir Singh Khanna ,  Mohan Prasad ,  Yatendra Kumar

IPC: C07D401/12

CPC classification number: C07D401/12

Abstract: The present invention relates to a process for enantioselective synthesis of substituted pyridinylmethyl sulfinyl-benzimidazole of compound of Formula (I). The process includes enantioselective catalytic oxidation of a substituted pyridinylmethyl prochiral sulfide derivative of compound of Formula (II) with an oxidizing agent in the presence of a chiral transition metal complex and a base in the absence of an organic solvent.

Abstract translation: 本发明涉及式（I）化合物的取代的吡啶基甲基亚磺酰基 - 苯并咪唑的对映选择性合成方法。 该方法包括式（II）化合物的取代的吡啶基甲基前手性硫化物衍生物在手性过渡金属络合物和碱的存在下，在不存在有机溶剂的情况下与氧化剂的对映选择性催化氧化。

公开(公告)号：US20100228030A1

公开(公告)日：2010-09-09

申请号：US12666606

申请日：2008-06-28

Applicant: Dattatray B. Patil ,  Killol Patel ,  Ashok Prasad ,  Mohan Prasad

Inventor： Dattatray B. Patil ,  Killol Patel ,  Ashok Prasad ,  Mohan Prasad

IPC: C07D471/14 ,  C07D471/04

CPC classification number: C07D471/14 ,  C07D471/04 ,  C07D471/12

Abstract: The present invention relates to a process for the preparation of cis-intermediates of Formula II, (Formula II) wherein R1 represents hydrogen, (un)substituted alkyl, alkenyl, aryl, and X represents a leaving group, which are useful synthetic intermediates in the preparation of tetracyclic compounds having phosphodiesterase inhibitory activity.

Abstract translation: 本发明涉及一种制备式II的顺式 - 中间体的方法（式II），其中R 1表示氢，（取代的）取代的烷基，烯基，芳基，X表示离去基团，它们是有用的合成中间体 制备具有磷酸二酯酶抑制活性的四环化合物。

公开(公告)号：US20100210847A1

公开(公告)日：2010-08-19

申请号：US12669553

申请日：2008-07-17

Applicant: Ashish M. Trivedi ,  Shailendra Kumar Singh ,  Neera Tewari ,  Mohan Prasad

Inventor： Ashish M. Trivedi ,  Shailendra Kumar Singh ,  Neera Tewari ,  Mohan Prasad

IPC: C07D401/12

CPC classification number: C07D401/12

Abstract: The present invention relates to a process for the preparation of pantoprazol sodium sesquihydrate of formula (I) and pantoprazole sodium.

Abstract translation: 本发明涉及制备式（I）泮托拉唑倍半水合物和泮托拉唑钠的方法。

公开(公告)号：US20100137607A1

公开(公告)日：2010-06-03

申请号：US12703004

申请日：2010-02-09

Applicant: Yatendra KUMAR ,  Mahavir Singh Khanna ,  Mohan Prasad

Inventor： Yatendra KUMAR ,  Mahavir Singh Khanna ,  Mohan Prasad

IPC: C07D401/12

CPC classification number: C07D401/12 ,  A61K31/4439

Abstract: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.